Experimental vaccine boosts survival in aggressive brain cancer patients

An experimental personalized vaccine against glioblastoma extended the lives of four patients by up to 50%. The vaccine, developed by scientists at the University of Florida, uses lipid particles to train the immune system to target tumor cells. A larger trial with 24 patients is planned to confirm safety and dosage. Previous animal trials showed promising results. The study was published in the journal Cell.